PharmAust media thread, page-314

Interesting article, thanks for posting.

I'm not sure I would classify all the drugs listed as competitors to MPL though:


ABBVCLS-7262 may be, I am not across it enough to say for sure either way. It is also targeting TPD43 but the mechanism appears to be different so could be complementary.
I would be interested to hear from anyone who has a better grasp of how this drug compares to MPL?

AP-01 appears to be targeting the SOD1 variant (MPL is not, Patients at risk of or known to carry a SOD1 mutation or VCP mutation were excluded from the MPL trial)

CNMAU-8: I believe this has a different target (ie not autophagy) so may be complementary - I would be keen to hear more from anyone who has a good grasp of this?

RAPA-501 This is an open-label, non-randomized, multi-center intermediate size expanded access clinical trial of single-agent RAPA-501 cells in patients with high-risk ALS who are not eligible for other ALS clinical trials.